Skyrizi Pen coupons
Skyrizi Pen

Skyrizi Pen Coupons & Savings Card – Discount Prices from $22726.44

Risankizumab is prescribed for the treatment of plaque psoriasis and psoriatic arthritis, as well as specific bowel diseases like Crohn's disease and ulcerative colitis. As a monoclonal antibody, it functions by inhibiting interleukin-23, a natural protein in the body that can lead to inflammation and swelling.

My prescription

Edit

1ML of 150MG/ML, Skyrizi Pen (1 Pen)

Select pharmacy

See local prices

Albertsons logo

Albertsons

$22,726.44

COUPON PRICE
Walgreens logo

Walgreens

$23,466.05

COUPON PRICE
Walmart logo

Walmart

$24,751.78

COUPON PRICE

Skyrizi Pen savings card

Show this card to your pharmacist
albertsons logo

Albertsons

$22,726.44

BIN

ID

PCN

GRP

019876

LH51B8682B

CHIPPO

LHX

Powered by

This coupon is not insurance

Price history for Skyrizi Pen

1 Pen, 1ML of 150MG/ML

Average retail price for Skyrizi Pen

Average SaveHealth price for Skyrizi Pen

Our price history data is based on aggregated prescription data collected from participating pharmacies in America. Our prescription data updates daily to reflect the latest price changes. If you notice a missing data point, it means there wasn't sufficient data available to generate a monetary value for that date.

*Retail prices are based on pharmacy claims data, and may not be accurate when we don't have enough claims.

Skyrizi Pen dosage forms

Use our Skyrizi Pen 1ML of 150MG/ML coupon with prices from $22,726.44 for 1 Pen. You can also use our Skyrizi Pen 1ML of 150MG/ML coupon with prices from $45,436.55 for 2 Pens. We have a Skyrizi Pen 1ML of 150MG/ML coupon with prices from $68,146.67 for 3 Pens.
DosageQuantityPrice fromPer unit
1ML of 150MG/ML1 Pen$22,726.44$22,726.44
1ML of 150MG/ML2 Pens$45,436.55$22,718.28
1ML of 150MG/ML3 Pens$68,146.67$22,715.56
Skyrizi Pen FAQs
What is a SKYRIZI pen?

The SKYRIZI pen is a pre-filled injection device used to administer the medication risankizumab, which is prescribed for the treatment of certain inflammatory conditions such as plaque psoriasis. The pen is designed for ease of use, allowing patients to self-administer the medication subcutaneously, typically under the guidance of a healthcare provider.

SKYRIZI is used to treat moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy. It is also approved for the treatment of active psoriatic arthritis in adults.

SKYRIZI is not approved for the treatment of Crohn's disease. It is primarily used for plaque psoriasis and psoriatic arthritis. For Crohn's disease, other medications are typically prescribed, and the dosing schedule for SKYRIZI would not be applicable. It is important to consult a healthcare provider for appropriate treatment options for Crohn's disease.

SKYRIZI pen is used to treat moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy. It is also used for the treatment of active psoriatic arthritis in adults.

Weight loss is not commonly reported as a side effect of SKYRIZI (risankizumab-rzaa). If a patient experiences unexpected weight changes while taking this medication, it is advisable to consult with a healthcare provider to determine the cause and appropriate action.